Clinical Trials in Los Angeles

Showing 5221-5240 of 16,901 trials

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

Cancer

MiraKind15,000 participantsStarted Sep 2014

Los Angeles, California, United States

COMPLETEDPhase 2< 1 mile

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465

This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.

Diabetic Foot Ulcer

Anterogen Co., Ltd.66 participantsStarted Jan 2019

Los Angeles, California, United States

COMPLETEDPhase 1/2< 1 mile

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

NCT01261312

Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.

MDSCMMLAML

Astex Pharmaceuticals, Inc.414 participantsStarted Jan 2011

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Haven, Connecticut, United States +13 more locations

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Find Trials by Condition in Los Angeles

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Novel Experimental COVID-19 Therapies Affecting Host Response

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities

Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy

Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Non-Complex Biliary Stones DSC vs ERC

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)